Skip to content
OpenCapital
Get started

Opko Health OPK Diagnostics — Research And Development Expense

Other segment segments

Pharmaceutical
$28.75M-4.9%

Similar metrics at other companies

Abbott logo
ABTDiagnostic Products — R&D
$155M+2.6%
Revvity logo
RVTYDiagnostics — Segment research and development expenses
$26.21M+3.7%
Thermo Fisher Scientific logo
TMOSpecialty Diagnostics — Research and development expenses
$44M-2.2%
Agilent Technologies logo
ALife Sciences and Diagnostics Markets — Research and Development Expense
$64M+8.5%
TEC
TECHDiagnostics And Spatial Biology — Research And Development Expense Excluding Acquired In Process Cost
$9M-11.7%
Medtronic logo
MDTDiabetes — Research and development expense
$109M+0.9%

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B+10.0%
P/S1.9×+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0×0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's diagnostics — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's diagnostics — research and development expense?
Opko Health (OPK) reported diagnostics — research and development expense of $312K in Q1 2026.
How has Opko Health's diagnostics — research and development expense changed year-over-year?
Opko Health's diagnostics — research and development expense decreased by 42.0% year-over-year, from $538K to $312K.
What is the long-term trend for Opko Health's diagnostics — research and development expense?
Over 3 years (2022 to 2025), Opko Health's diagnostics — research and development expense has grown at a -48.6% compound annual growth rate (CAGR), from $12.02M to $1.64M.
What does diagnostics — research and development expense mean?
Represents the costs incurred for developing new diagnostic technologies, improving existing testing methodologies, and clinical validation. This investment is vital for maintaining a competitive edge in the rapidly evolving diagnostics market. High spending indicates a commitment to innovation and future product pipeline expansion.